

Heather A Wakelee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7725269/publications.pdf>

Version: 2024-02-01

160
papers

11,047
citations

50170

46
h-index

32761

100
g-index

162
all docs

162
docs citations

162
times ranked

14382
citing authors

#	ARTICLE	IF	CITATIONS
1	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , 2014, 20, 548-554.	15.2	1,771
2	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	9.4	837
3	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
4	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	5.8	520
5	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	0.5	515
6	Lung Cancer Incidence in Never Smokers. <i>Journal of Clinical Oncology</i> , 2007, 25, 472-478.	0.8	498
7	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
8	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 946-953.	0.8	377
9	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	0.5	274
10	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
11	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
12	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
13	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	3.2	141
14	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1610-1623.	5.1	136
15	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
16	Lung Cancer in Never Smokers. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 43-57.	0.8	122
17	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	1.9	119
18	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1617.	3.4	105

#	ARTICLE	IF	CITATIONS
19	Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 339-346.	0.7	101
20	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	0.5	101
21	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1745-1753.	0.5	100
22	KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
23	Risk Stratification for Second Primary Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2893-2899.	0.8	92
24	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	3.3	90
25	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. <i>Lung Cancer</i> , 2019, 133, 144-150.	0.9	90
26	ERBB2 -Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 833-842.	0.5	86
27	Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 52-58.	1.1	83
28	The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1371-1382.	1.1	81
29	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 115, 129-135.	2.9	80
30	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	6.6	80
31	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	0.5	79
32	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	3.2	75
33	Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. <i>Clinical Lung Cancer</i> , 2014, 15, 202-206.	1.1	68
34	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. <i>American Journal of Ophthalmology</i> , 2015, 160, 799-805.e1.	1.7	68
35	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	0.9	67
36	Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 231-237.	0.4	66

#	ARTICLE	IF	CITATIONS
37	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	3.2	63
38	Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. <i>Journal of Thoracic Oncology</i> , 2017, 12, 129-136.	0.5	62
39	Review of the current targeted therapies for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 576.	0.9	59
40	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>in Vivo</i> . <i>Cancer Discovery</i> , 2021, 11, 1736-1753.	7.7	59
41	Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2021, 3, 137-139.	1.7	55
42	Tobacco Smoking and Risk of Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 968-979.	0.5	54
43	Changes in the natural history of nonsmall cell lung cancer (NSCLC) – Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. <i>Cancer</i> , 2006, 106, 2208-2217.	2.0	53
44	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	7.7	51
45	miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. <i>Chest</i> , 2013, 144, 1632-1643.	0.4	50
46	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 116-129.	0.5	50
47	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
48	A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1574-1582.	0.5	48
49	Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy. <i>Seminars in Oncology</i> , 2014, 41, 40-56.	0.8	46
50	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1004-1013.	0.5	44
51	Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study. <i>Annals of the American Thoracic Society</i> , 2016, 13, 58-66.	1.5	44
52	Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. <i>Journal of Thoracic Oncology</i> , 2006, 1, 441-6.	0.5	43
53	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 868-872.	0.5	42
54	Radiological tumour classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021, 3, 787-798.	8.3	41

#	ARTICLE	IF	CITATIONS
55	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
56	Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2250-2265.	1.1	38
57	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 42-45.	0.9	37
58	Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 403-10.	1.3	36
59	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 50-59.	1.1	35
60	Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. <i>Oncologist</i> , 2019, 24, 836-843.	1.9	34
61	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2029-2039.	0.5	34
62	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 395-403.	0.5	33
63	Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016, 139, 2178-2192.	2.3	31
64	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 42-47.	0.9	31
65	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. <i>Oncimmunology</i> , 2020, 9, 1824645.	2.1	31
66	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 10-17.e1.	1.1	30
67	Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016, 34, 360-368.	0.8	29
68	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 338-343.	0.3	29
69	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. <i>Lung Cancer</i> , 2015, 87, 34-38.	0.9	27
70	A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. <i>Journal of Clinical Oncology</i> , 2016, 34, 3019-3019.	0.8	27
71	Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years. <i>Lung Cancer</i> , 2017, 108, 140-149.	0.9	26
72	Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 545-554.	1.1	25

#	ARTICLE	IF	CITATIONS
73	Lung Cancer Survival Among Chinese Americans, 2000 to 2010. <i>Journal of Global Oncology</i> , 2016, 2, 30-38.	0.5	24
74	Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 767-778.	0.5	24
75	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. <i>Clinical Lung Cancer</i> , 2021, 22, 201-209.	1.1	24
76	Targeting Angiogenesis with Vascular Endothelial Growth Factor Receptor Small-Molecule Inhibitors: Novel Agents with Potential in Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, S31-S38.	1.1	23
77	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 366-373.	1.1	23
78	Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e21-e24.	0.5	23
79	Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females. <i>Journal of the National Cancer Institute</i> , 2022, 114, 78-86.	3.0	23
80	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. <i>Current Treatment Options in Oncology</i> , 2017, 18, 71.	1.3	22
81	Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. <i>Cancer Medicine</i> , 2018, 7, 1211-1220.	1.3	22
82	Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e581-e588.	1.1	22
83	Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 346-351.	1.1	21
84	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. <i>Cancer Epidemiology</i> , 2015, 39, 307-312.	0.8	21
85	Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 989-993.	0.9	19
86	Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series. <i>Translational Lung Cancer Research</i> , 2021, 10, 487-495.	1.3	19
87	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	3.2	19
88	Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. <i>Lung Cancer</i> , 2015, 89, 280-286.	0.9	18
89	Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. <i>Gerontologist</i> , 2016, 56, S102-S111.	2.3	18
90	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 563-571.	1.1	16

#	ARTICLE	IF	CITATIONS
91	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e148-e153.	1.1	16
92	Antibodies to Vascular Endothelial Growth Factor in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, S113-S118.	0.5	15
93	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. <i>Lung Cancer</i> , 2015, 90, 1-7.	0.9	14
94	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 72.	2.0	14
95	Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 16-21.	0.4	14
96	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. <i>Clinical Chemistry</i> , 2021, 67, 534-542.	1.5	14
97	The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 618-625.	3.0	13
98	Everolimus in the treatment of metastatic thymic epithelial tumors. <i>Lung Cancer</i> , 2020, 149, 97-102.	0.9	12
99	Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e193-e200.	1.1	12
100	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. <i>Clinical Therapeutics</i> , 2016, 38, 1567-1576.	1.1	11
101	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 173-182.	0.9	11
102	Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California. <i>PLoS ONE</i> , 2018, 13, e0197146.	1.1	11
103	Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. <i>Lung Cancer</i> , 2019, 137, 71-75.	0.9	11
104	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100114.	0.6	11
105	Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 264-272.	1.1	11
106	Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. <i>Clinical Lung Cancer</i> , 2022, 23, e210-e221.	1.1	11
107	Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 198-203.	0.4	10
108	A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100174.	0.7	10

#	ARTICLE	IF	CITATIONS
109	Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 87-96.	3.0	10
110	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e208-e217.	1.1	9
111	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	8
112	Metabolomic profiling for second primary lung cancer: A pilot case-control study. <i>Lung Cancer</i> , 2021, 155, 61-67.	0.9	8
113	Integrating Electronic Health Record, Cancer Registry, and Geospatial Data to Study Lung Cancer in Asian American, Native Hawaiian, and Pacific Islander Ethnic Groups. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1506-1516.	1.1	8
114	Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab076.	1.4	8
115	Novel approaches for the treatment of small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 499-518.	0.9	7
116	Activity of Novel Cytotoxic Agents in Lung Cancer: Etoposides and Topoisomerase I Inhibitors. <i>Clinical Lung Cancer</i> , 2005, 7, S6-S12.	1.1	7
117	Docetaxel in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 13-24.	1.1	7
118	Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1994-1998.	0.5	7
119	Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	7
120	Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 9-15.	1.1	6
121	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 815-824.	1.1	6
122	Neoadjuvant and Adjuvant Therapy for Non-small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 31-44.	0.9	6
123	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 219-227.	0.6	6
124	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	7.7	6
125	Elusive Target of Angiogenesis in Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1269-1271.	0.8	5
126	Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e153-e156.	1.1	5

#	ARTICLE	IF	CITATIONS
127	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. <i>Anticancer Research</i> , 2015, 35, 669-76.	0.5	5
128	Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. <i>Clinical Lung Cancer</i> , 2009, 10, 395-404.	1.1	4
129	Pretreatment biopsy for thymic epithelial tumors—does histology subtype matter for treatment strategy?. <i>Journal of Thoracic Disease</i> , 2016, 8, 1895-1900.	0.6	4
130	Monitoring Neutropenia for Cancer Patients at the Point of Care. <i>Small Methods</i> , 2017, 1, 1700193.	4.6	4
131	PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. <i>Clinical Lung Cancer</i> , 2021, 22, e329-e335.	1.1	4
132	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021, 26, 523-532.	1.9	4
133	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 153-162.	1.5	4
134	A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8576-TPS8576.	0.8	4
135	Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. <i>Neuro-Oncology Advances</i> , 2021, 3, v52-v62.	0.4	4
136	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100497.	0.7	4
137	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	3
138	A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 541-550.	1.1	3
139	Response to comment on “Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes”. <i>Lung Cancer</i> , 2019, 137, 159-160.	0.9	2
140	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. <i>Clinical Lung Cancer</i> , 2021, 22, e673-e677.	1.1	2
141	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1479-1489.	0.5	2
142	Novel Treatments for Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2015, 5, 267.	1.3	1
143	Reply to Comment on “Statin use and all-cancer survival: prospective results from the Women’s Health Initiative”. <i>British Journal of Cancer</i> , 2017, 116, e2-e2.	2.9	1
144	The J-ALEX trial—is frontline alectinib a new standard of care?. <i>Journal of Thoracic Disease</i> , 2017, 9, 2242-2245.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Caution Needed for Analyzing the Risks of Second Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, e172-e173.	0.5	1
146	Tumor Heterogeneity and Testing Discrepancy Confound ROS1 Detection in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e111-e113.	0.5	1
147	Adjuvant Chemotherapy. <i>Thoracic Surgery Clinics</i> , 2020, 30, 179-185.	0.4	1
148	Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival. <i>Annals of Translational Medicine</i> , 2018, 6, S118-S118.	0.7	1
149	Management of early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 315.	1.3	1
150	Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100274.	0.6	1
151	Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	1
152	Ancestry-based differences in gene alterations in non-small cell lung cancer: Real-world data using genetic ancestry analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9125-9125.	0.8	1
153	Genomic characterization of thymic epithelial tumor from real-world data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8587-8587.	0.8	1
154	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?: Response. <i>Chest</i> , 2013, 144, 1971-1972.	0.4	0
155	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 377-386.	1.1	0
156	A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, e59-e60.	0.5	0
157	Smoking and estrogen plus progestin (E+P) and lung cancer incidence and mortality.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1524-1524.	0.8	0
158	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 241-241.	0.8	0
159	Abstract PO-130: Disparities in risk of second primary lung cancer among lung cancer patients in the United States. , 2022, , .		0
160	In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?" <i>Journal of Thoracic Oncology</i> , 2022, 17, e12-e14.	0.5	0